



This poster documents the data elements within the Flux Notes pre encounter view, and the elements applied to an example interface. The items in blue are highest priority for the clinical oncologist to view. The Core SHR elements are those which should be present no matter the user or clinical domain. This document has not been accurately vetted with a clinician. It should be viewed as a rough draft for beginning the conversation to developing a refined list of data elements.

DISCUSSION POINTS

What data should always be displayed (core SHR information) regardless of user/use-case/condition?
What is all the necessary data for a pre-encounter oncologist view?
For the core SHR, as well as the pre-encounter oncologist view, what data is High / Medium / Low priority?

CORE SHR

GLOBAL / NAVIGATION

USER / MODE

Name of user
Use case

PATIENT SUMMARY

DEMOGRAPHIC / IDENTIFICATION

Patient name
MRN
DoB
Administrative gender
Location
Place of birth
Birth sex
Race
Ethnicity
Marital status
Mothers maiden name
Fathers name
Address
Telephone (home)
Telephone (mobile)
Language used
Chief complaint / condition

CONDITION

OVERVIEW OF CONDITIONS

Name of condition
Disease status
Event date
Diagnosis date

RELEVANT DATES

Procedures
Name
Date of procedure
Medical encounter
Date of medical encounter

PRE ENCOUNTER CARCINOMA OF BREAST VIEW

GLOBAL / NAVIGATION

USER / MODE


Name of user
Use case

Possible use cases:
Pre-encounter
Pre-surgery
Post-surgery
Follow-up
Review patient / consultation
Encounter
Post-encounter
Population health

PATIENT SUMMARY

DEMOGRAPHIC / IDENTIFICATION

Patient name
MRN
DoB
Administrative gender
Location
Place of birth
Birth sex
Race
Ethnicity
Marital status
Mothers maiden name
Fathers name
Address
Telephone (home)
Telephone (mobile)
Language used
Chief complaint / condition



Example interface

RECENT LAB RESULTS

Hemoglobin
WBC

MEDICATIONS

Medication Prescription
amount Per Dose
timing Of Doses
dose As Needed Indicato
Period Start
Period End

ALLERGIES

Summary			
Identification	Date recorded	Current diagnosis	Date recorded
Family name	Debra24	Name	Lobular carcinoma of the breast
Given name	Hernandez98Aj	Stage	IIA
Address	Date recorded	Progression	Stable
Street	14 Northeast Drive	Rationale	Physical exam
City, state	Boston, MA	Recent lab results	Value Unit Date recorded
Postal code	Missing postal code	Hemoglobin	6.30 % 8 Sep 2017
		White blood cell	2.12 109/L 8 Sep 2017

Summary

Ms. Debra24 Hernandez98Aj is a 51-year-old menopausal non hispanic or latino woman with invasive ductal carcinoma of the breast, diagnosed on 13 January 2012. Her most recent status, recorded on 15 May 2017, is of worsening, disease progression based on **pathology, imaging, and symptoms**.

She underwent a lumpectomy on 20 September 2012. She underwent a sentinel lymph node biopsy on 20 September 2012 which revealed infiltrating poorly differentiated ductal carcinoma, grade 3, estrogen receptor 0, etc. A diagnostic mammogram on 4 October 2013 revealed a 2 cm mass in the right breast at 7 o'clock and an indeterminate lymph node in the right axilla, 13 mm.

TIMELINE VIEW


BREAST CANCER TREATMENT DATA

Progression scale over time
Chemotherapy
WBC over time
Defined pathways
% compliance with pathways
Prescriptions
Name of prescription
Time interval of prescription
Dosage of prescription
Key events
Hospitalizations
Location of hospitalization
Date of hospitalization
Procedures
Name of procedure
Date of procedure

PAST MEDICAL HISTORY

PAST SURGICAL HISTORY

SOCIAL HISTORY



CONDITION

BREAST CANCER TREATMENT DATA

Name of condition
Current staging
Tumor
Node
Metastasis
Disease status
Status of disease
Rationale
Event date
Diagnosis date
Recurrence date
Toxicity assessment
Adverse event
Grade
Attribution
Pathology results
Oncotype DX recurrence score
Genetic testing
Best overall response
Target vs non-targeted lesion assessment
Radiology assessment
Risk factors

RELEVANT DATES

Procedures
Name
Date of procedure
Medical encounter
Date of medical encounter

PROTOCOL / PATHWAY

Clinical pathways
Protocol
Current protocol
Patients current place in protocol
Chemotherapy
Dose
Cycle
Regimen
Current regimen
Prior regimen(s)
Risk stratification for the patient

Lobular Carcinoma of the Breast

Condition summary	Pathway detail	Clinical notes
Current pathway		
Prevention	Screening	Diagnosis
		Treatment
		Palliative

Current diagnosis		Date recorded
Name	Lobular carcinoma of the breast	2 Jul 2017
Stage	IIA	2 Jul 2017
Progression	Stable	2 Aug 2017
Rationale	Physical exam	2 Aug 2017

Condition history		Date
Mammography		4 Oct 2013
Sentinel Lymph Node Biopsy		20 Sep 2012
Lumpectomy		20 Sep 2012

Current regimen

Medication	Dose	Frequency	Prescribed	End
Counadin	2 mg	1 daily	5 Sep 2015	31 May 2017
Aromasin	25 mg	1 daily	5 Jun 2017	31 Dec 2017

Chemotherapy regimen

Dose-dense AC followed by paclitaxel (category 1)

Chemotherapy medication	Date
Cyclophosphamide 600mg/m2 IV cycle 4	30 Oct 2017
Paclitaxel 175mg/m2, 3-hour IV infusion cycle 4	30 Oct 2017
Cyclophosphamide 600mg/m2 IV cycle 3	16 Oct 2017
Paclitaxel 175mg/m2, 3-hour IV infusion cycle 3	16 Oct 2017
Cyclophosphamide 600mg/m2 IV cycle 2	2 Oct 2017
Paclitaxel 175mg/m2, 3-hour IV infusion cycle 2	2 Oct 2017
Cyclophosphamide 600mg/m2 IV cycle 1	18 Sep 2017